Antipsychotic Discontinuation in High-risk Subjects
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01758887|
Recruitment Status : Withdrawn (administrative reason)
First Posted : January 1, 2013
Last Update Posted : October 13, 2016
- Would be there any difference in dopamine synthesis between remitted clinical high risk subjects for psychosis and healthy control?
- What would happen to dopamine synthesis after antipsychotic discontinuation in clinical high risk subjects for psychosis?
- What about the dopamine synthesis in recurred clinical high risk subjects for psychosis after the discontinuation?
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Observational Model:||Case Control|
|Official Title:||Antipsychotic Discontinuation in High-risk Subjects|
|Study Start Date :||December 2012|
|Estimated Primary Completion Date :||September 2016|
|Estimated Study Completion Date :||September 2016|
clinical high risk subjects for psychosis
- Presynaptic dopamine synthesis in the striatum [ Time Frame: baseline ]measured with [18F]DOPA positron emission tomography
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01758887
|Korea, Republic of|
|Seoul National University Hospital|
|Seoul, Korea, Republic of, 110-744|
|Principal Investigator:||Jun Soo Kwon, MD PhD||Seoul National University College of Medicine|